Withaferin A activates TRIM16 for its anti-cancer activity in melanoma

Zsuzsanna Nagy, Belamy B. Cheung*, Wing Tsang, Owen Tan, Mika Herath, Olivia C. Ciampa, Fatima Shadma, Daniel R. Carter, Glenn M. Marshall

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Although selective BRAF inhibitors and novel immunotherapies have improved short-term treatment responses in metastatic melanoma patients, acquired resistance to these therapeutics still represent a major challenge in clinical practice. In this study, we evaluated the efficacy of Withaferin A (WFA), derived from the medicinal plant Withania Somnifera, as a novel therapeutic agent for the treatment of melanoma. WFA showed selective toxicity to melanoma cells compared to non-malignant cells. WFA induced apoptosis, significantly reduced cell proliferation and inhibited migration of melanoma cells. We identified that repression of the tumour suppressor TRIM16 diminished WFA cytotoxicity, suggesting that TRIM16 was in part responsible for the cytotoxic effects of WFA in melanoma cells. Together our data indicates that WFA has potent cytopathic effects on melanoma cells through TRIM16, suggesting a potential therapeutic application of WFA in the disease.

Original languageEnglish
Article number19724
Number of pages9
JournalScientific Reports
Volume10
Issue number1
DOIs
Publication statusPublished - 12 Nov 2020
Externally publishedYes

Bibliographical note

Copyright © The Author(s) 2020. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Fingerprint Dive into the research topics of 'Withaferin A activates TRIM16 for its anti-cancer activity in melanoma'. Together they form a unique fingerprint.

Cite this